Testing monotherapy and combination therapy in one trial with biomarker consideration

Area of Science:

• Clinical trial design
• Biomarker-driven oncology therapeutics
• Pharmaceutical development

Background:

• Experimental oncology therapies can show differential efficacy based on biomarker status.
• Combination therapies may offer benefits in unselected patient populations.
• Current development often requires separate Phase III trials for monotherapy and combination strategies.

Purpose of the Study:

• To propose an integrated one-trial design for evaluating oncology therapies.
• To improve efficiency and reduce the family-wise error rate (FWER) compared to traditional methods.
• To address the specific statistical challenges of a skewed comparison population in the proposed design.

Main Methods:

• A novel one-trial design stratifying patients by biomarker status.
• Biomarker-positive patients randomized to combination therapy, monotherapy, or standard of care (SOC).
• Biomarker-negative patients randomized to combination therapy or SOC.
• A two-step log-rank statistic proposed to handle skewness in the combination vs. SOC comparison.
• Evaluation of power and sample size compared to the conventional two-trial paradigm.

Main Results:

• The proposed one-trial design achieves a smaller FWER than two separate trials due to shared control.
• No FWER adjustment is necessary, allowing testing at a 2.5% one-sided alpha level.
• The proposed design demonstrates greater efficiency in terms of power and sample size requirements.

Conclusions:

• The proposed one-trial design offers a more efficient and statistically robust approach for oncology drug development.
• This integrated design can streamline the evaluation of both monotherapy and combination treatments.
• The statistical methods proposed effectively address the unique challenges of this novel trial structure.